Oral sirolimus in the treatment of adult eruptive cherry angiomas
- Author:
Christine Lyka R. Sayson, MD
1
;
Aira Monica R. Abella, MD
1
;
Danielle Marlo R. Senador, MD
1
;
Leilani R. Senador, MD, FPDS
1
;
Gisella U. Adasa, MD, FPDS
1
Author Information
- Publication Type:Case Reports
- Keywords: eruptive hemangiomas; cherry angiomas
- MeSH: sirolimus; vascular malformation
- From: Journal of the Philippine Dermatological Society 2023;32(1):35-38
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Cherry angiomas are a common type of acquired vascular proliferation of the skin which manifest as single or multiple
bright red spots that usually appear on the trunk and arms. They are generally asymptomatic; patients may opt to remove the lesions for
cosmetic reasons and prevention of bleeding. Conventionally, most cherry angiomas are treated with curettage, laser, and electrosurgery. Herein, we report a case of multiple cherry angiomas managed alternatively with oral sirolimus.
Case:A 47-year-old Filipino female presented with a 10-month history of gradually enlarging multiple bright-red papules and pedunculated nodules with a propensity to spontaneously bleed on gentle manipulation involving the scalp and forehead. Clinicopathological correlation suggests a diagnosis of eruptive cherry angiomas. The patient was started on oral sirolimus, a mammalian target of rapamycin (mTOR) inhibitor.
Conclusion:We present a case of a patient with eruptive cherry angiomas who experienced significant decrease in size and bleeding with treatment of oral sirolimus with minimal adverse effects. For patients with eruptive cherry angiomas, especially with contraindicated comorbidities, first-line therapeutic option treatments with oral sirolimus can be beneficial. - Full text:JPDS 71.pdf
